A PHASE IV, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APRIMELAST TREATMENT ON JOINT SPACE NARROWING IN PATIENTS WITH PSORIASIS ARTHRITIS (MOASIC): RATIONALE, DESIGN AND METHODS


1 University of Copenhagen, Copenhagen, Denmark; 2University of Alberta, Edmonton, Canada; 3Boehringer Ingelheim, Munich, Germany; 4Image Analysis Group, London, United Kingdom; 5Cellegene Corporation, Summit, New Jersey, USA; 6Swedish Medical Center and University of Washington School of Medicine, Seattle, United States of America

Background: Phase III clinical trials have shown apremilast (APR) reduced PsA signs/symptoms and improved physical function, but no study has addressed its impact on structural disease progression. MRI is a highly sensitive, validated tool to assess inflammatory and structural changes, as it can detect soft tissue inflammation, bone marrow edema (BME) lesions, bone erosion and proliferation in peripheral joints and axial skeleton. Whole-body (WB)-MRI, a relatively novel technique in musculoskeletal studies, allows assessment of all peripheral/axial joints and entheses in 1 examination. Recent, consensus-based and semi-quantitative scoring methods were developed and validated. This study is the first to systematically use new state-of-the-art MRI scoring methodologies to assess PsA inflammatory and structural changes in a global clinical trial.

Objectives: To assess APR efficacy on inflammatory indices and imaging outcome measures associated with PsA structural progression by conventional static MRI and dynamic contrast-enhanced (DCE)-MRI of the most affected hand and WB-MRI.

Methods: The study aims to enroll 120 biologic-naïve adults with PsA for ≥3 mos to ≤5 yrs and prior treatment with ≤2 conventional DMARDs. Subjects must have ≥3 swollen and ≥3 tender joints, hand involvement (≥1 swollen joint or ≥1 dactylitis) and ≥1 active enthesitis site. After 4-wk screening, all eligible patients will receive APR 30 mg twice daily (titrated during the first 5 days) as monotherapy or in combination with methotrexate for 48 wks, with a 4-wk observational follow-up. Conventional MRI and optional DCE-MRI of the most affected hand and WB-MRI of the entheses will be performed at Wks 0, 24 and 48. The primary endpoint is change from BL to WK 24 in OMERACT PsA MRI (PsAMRIS) composite score of BME + synovitis + tenosynovitis. Other imaging endpoints include change from BL to WK 48 in PsAMRIS composite score (BME + synovitis + tenosynovitis) and change from BL to Wks 24 and 48 in PsAMRIS composite score (BME + synovitis), PsAMRIS composite inflammation score (BME + synovitis + tenosynovitis + periarticular inflammation), PsAMRIS total damage score (erosion + bone proliferation), WB-MRIs (including peripheral joint inflammation index and peripheral enthesis inflammation index), hip and knee inflammation MRI scores (HIMRIS, KIMRIS), OMERACT heel enthesitis MRI indices, axial inflammation indices (SPARC, CnDen), DEMRIQ-Volume and DEMRIQ-Inflammation and other DCE-MRI-derived parameters. Clinical parameters will include SJC/TJC, cDAPSA, SPARC Enthesis Index, Leeds Enthesis Index, Leeds Dactylitis Index, PASDAS, PtGA, PhGA, Patient’s Assessment of Pain, HAQ-DI, and BASDAI and impact of disease (PsAID12). Safety and tolerability will also be assessed.

Results: The study protocol was approved by an independent ethics committee and is now enrolling in the USA. Selected countries in Europe and Russia will also participate. MRI, clinical and patient-reported outcomes will be analyzed.

Conclusion: This study will provide important evidence of APR’s impact on inflammatory/structural changes by assessing all PsA musculoskeletal domains (peripheral arthritis, enthesitis, dactylitis and axial disease). Furthermore, it will yield information on use of conventional MRI–, WB-MRI– and DCE-MRI-driven outcome measures in PsA clinical trials.

REFERENCES


Disclosure of Interests: Mikkel Østergaard Grant/research support from: Abbvie, Celgene, Centocor, Merck, Novartis, Consultant for: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novar- is, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, Walter P Maksymyowych Grant/research support from: AbbVie, Pfizer, Janssen, Novartis, Consultant for: AbbVie, Eli Lilly, Boehringer, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma; Chief Medical Officer for Canadian Research and Education Arthritis, Mikael Boesen Shareholder of, Image Analysis Group, Olga Kubassova Shareholder of: IAG, Image Analysis Group, Employee of: IAG, Image Analysis Group, Priscila Nakasato Employee of: Cellegene Corporation, Benoit Guerette Employee of: Cellegene Corporation, Lichen Teng Employee of: Cellegene Corporation, Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB


COMPUTER-BASED EVALUATION OF JOINT SPACE NARROWING IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL

Alexander Pfeil1, Arica Nussbaum2,2, Diane Renz3, Ansgar Malich2, Joachim Böttcher2, Gunter Wolf2, Peter Oelzner6,1. 1Jena University Hospital– Friedrich Schiller University Jena, Department of Internal Medicine III, Jena, Germany; 2Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany; 3Suedharz Klinikum Nordhausen, Institute of Diagnostic and Interventional Radiology, Nordhausen, Germany; 4SH Waldklinikum Gera, Institute of Diagnostic and Interventional Radiology, Gera, Germany

Background: The reduction of joint space width in patients with rheumatoid arthritis (RA) is associated with joint destruction. Anti-TNF treatment with certolizumab pegol is an effective therapy in RA-patients. The computer-assisted joint space analysis is a new computer based technique to measure joint space width on hand radiographs.

Objectives: The aim of this post-hoc analysis of the data set used in the RAPID 1 trial was to quantify finger joint space width of RA patients treated with Certolizumab pegol.

Methods: The post-hoc analysis includes 328 patients. These patients were divided into three groups: methotrexate plus placebo, certolizumab pegol 200 mg (every two weeks) plus methotrexate, and certolizumab pegol 400 mg (every two weeks) plus methotrexate. All patients underwent x-rays of the hand at baseline and week 52 as well as the quantification of finger joint space width of the metacarpal-phalangeal articulations (MCP) using the computer-assisted joint space analysis (Version 1.3.6, Sectra; Sweden). The joint space distance is expressed as mean joint space width of the MCP joints I to V (JSD-MCP total).

Results: The methotrexate group presented a significant joint space reduction with -4.8% for JSD-MCP total from 0.151 ± 0.028 cm (baseline) to 0.144 ± 0.036 cm (week 52) was observed. A similar result was evaluated for the certolizumab pegol 200 mg group (JSD-MCP total: 0.147 ± 0.035 cm [baseline] to 0.147 ± 0.036 cm [week 52]).

Conclusion: The study highlights that patients treated with certolizumab pegol plus methotrexate show no change of joint space width of the metacarpal-phalangeal articulations in comparison to patients with methotrexate plus placebo estimated by computer-assisted joint space analysis. Consequently, the automatic quantification of finger joint space is a sensitive technique for the quantification of joint space reduction and treatment monitoring.

REFERENCES


Disclosure of Interests: Alexander Pfeil Grant/research support from: This study is a part of the Investigator Initiated Study “The quantification of inflammatory related periarticular bone loss in certolizumab pegol treated patients with rheumatoid arthritis” which is funded and supported by UCB Pharma GmbH, Monheim, Germany (number: IIS-2014-101458),. Arica Nussbaum: None declared, Diane Renz: None declared, Ansgar Malich: None declared, Joachim Böttcher: None declared, Gunter Wolf: None declared, Peter Oelzner: None declared